Allergan plc (NYSE:AGN) CFO Matthew M. Walsh acquired 1,000 shares of the firm’s stock in a transaction dated Thursday, March 8th. The stock was bought at an average price of $153.96 per share, with a total value of $153,960.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Allergan plc (NYSE:AGN) opened at $157.28 on Friday. The firm has a market cap of $53,470.00, a P/E ratio of -13.12, a P/E/G ratio of 1.08 and a beta of 1.29. Allergan plc has a 1-year low of $142.81 and a 1-year high of $256.80. The company has a current ratio of 1.16, a quick ratio of 1.06 and a debt-to-equity ratio of 0.38.
Allergan (NYSE:AGN) last issued its earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.74 by $0.12. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.43%. The firm had revenue of $4.33 billion during the quarter, compared to analysts’ expectations of $4.28 billion. During the same period last year, the firm posted $3.90 earnings per share. The firm’s revenue for the quarter was up 12.0% compared to the same quarter last year. equities research analysts predict that Allergan plc will post 15.58 EPS for the current fiscal year.
A number of institutional investors have recently bought and sold shares of the stock. KCM Investment Advisors LLC boosted its stake in Allergan by 13.4% in the 4th quarter. KCM Investment Advisors LLC now owns 38,335 shares of the company’s stock worth $6,271,000 after purchasing an additional 4,539 shares during the period. Colonial Trust Advisors acquired a new position in Allergan in the 4th quarter worth approximately $470,000. Penbrook Management LLC acquired a new position in Allergan in the 4th quarter worth approximately $978,000. Massmutual Trust Co. FSB ADV boosted its stake in Allergan by 6.9% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 15,342 shares of the company’s stock worth $16,161,000 after purchasing an additional 994 shares during the period. Finally, Pin Oak Investment Advisors Inc. acquired a new position in Allergan in the 4th quarter worth approximately $1,787,000. 81.39% of the stock is owned by hedge funds and other institutional investors.
Several research analysts have recently issued reports on the stock. Credit Suisse Group set a $215.00 price objective on shares of Allergan and gave the company a “buy” rating in a report on Thursday, March 1st. Morgan Stanley decreased their price objective on shares of Allergan from $200.00 to $181.00 and set an “overweight” rating for the company in a report on Thursday, March 1st. SunTrust Banks assumed coverage on shares of Allergan in a report on Friday, February 23rd. They issued a “buy” rating and a $200.00 price objective for the company. They noted that the move was a valuation call. Bank of America increased their price objective on shares of Allergan from $208.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, February 7th. Finally, Leerink Swann increased their price objective on shares of Allergan from $237.00 to $242.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $225.03.
COPYRIGHT VIOLATION NOTICE: “Insider Buying: Allergan plc (AGN) CFO Buys 1,000 Shares of Stock” was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3253031/insider-buying-allergan-plc-agn-cfo-buys-1000-shares-of-stock.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.